MALIN CORP had an eventful history after Kelly Martin raised €400m when floating it in 2015. Unfortunately for investors, the plan to back small pharma entities and turn them into something like unicorns failed to deliver and Martin exited in 2018, admittedly after trousering a huge chunk of cash. Today things are looking an awful lot… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!